Eden Biodesign and Borean Pharma sign deal to develop novel cancer treatment
UK-based Eden Biodesign, a leading provider of development and manufacturing services for new biopharmaceutical medicines, and Borean Pharma, of Denmark, have signed an agreement under which Eden will manufacture MBP-DC-SIGN, a novel therapeutic candidate for the treatment of a range of cancers, for Borean to use in key preclinical studies.
UK-based Eden Biodesign, a leading provider of development and manufacturing services for new biopharmaceutical medicines, and Borean Pharma, of Denmark, have signed an agreement under which Eden will manufacture MBP-DC-SIGN, a novel therapeutic candidate for the treatment of a range of cancers, for Borean to use in key preclinical studies.
The project will be conducted at Eden Biodesign's state of the art facility in Liverpool and is expected to complete early in 2008.
MBP-DC-SIGN is one of Borean's products to be based on the Mannose-Binding protein (MBP) platform. The MBP platform is delivering a series of highly potent therapeutics for the treatment of cancers, and is the only scaffold that can induce complement-induced lysis.
"Working with Eden Biodesign will allow us to rapidly progress the development of this promising drug candidate," said Dr Johanna Holldack, ceo of Borean Pharma.
This agreement is the fourth contract to be announced by Eden Biodesign in recent weeks, and follows announcements for cGMP manufacturing and development projects with CRUK, University of Birmingham and UMIP.